Infectious Disease Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
The major factors for the growth of the infectious disease drugs market include the rising awareness activities by various government and non-profit organizations, increasing prevalence of infectious diseases, and the rising funding for the research and development.
The rising prevalence of infectious diseases is expected to boost the overall growth of the market over the forecast period. According to the World Health Organization (WHO), it is estimated that in 2018, nearly 37.9 million individuals had HIV, globally. It has been identified that most of this prevalence is in low and middle-income countries, with an estimated 66% living in Sub-Saharan Africa.
Similarly, as per the WHO's 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases. Thus, rising cases of infectious diseases are expected to increase the demand for infectious drugs resulting in the high growth of the market.
The high prevalence of malaria and other infections; increasing incidence of these conditions; and rising expenditure on the prevention and diagnosis of infectious diseases are likely to be the key factors responsible for the growth of this market. According to the WHO Report, Africa has been found to have the highest rate of malaria. Therefore, between 2000 and 2015, an expansion of malaria interventions has helped to reduce malaria incidence by 37% globally, and by 42% in Africa.
There are also various initiatives focusing on disease prevention are being undertaken globally. Furthermore, the government, private, and nonprofit organizations are also focusing on increasing the management of these diseases. Hence all these factors are expected to drive the overall market growth.
The United States is expected to be the largest infectious disease drug market owing to the rising prevalence of infectious diseases and the presence of better healthcare infrastructure. As per the Centers for Disease Control and Prevention (CDC), in 2017, a total of 9,093 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.8 cases per 100,000 population.
Furthermore, the antibiotic prescription rate is relatively high in the United States. In addition, the trend varies significantly, based on the provider in a particular state. Also, there is a rising prevalence of HIV in the United States and there is a rise in approval for the new disease treatment which is expected to boost the growth of the market. Thus, owing to the all above mentioned factors the market is expected to witness high growth over the forecast period.
The market studied is a fragmented market owing to the presence of various market players. Some of the market players are AbbVie Inc, Boehringer Ingelheim GmbH, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, Merck & Co., Inc., Novartis AG, Pfizer Inc, Sanofi SA, and Takeda Pharmaceutical Company Limited.